Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
UK cancer immunotherapy firm Immodulon has appointed Richard Couch as chief technology officer and Owen Vaughan as chief regulatory officer. 26 June 2023
San Diego, USA-based Solve Therapeutics (SolveTx) has announced the acquisition of privately-held radiotherapeutics and radiodiagnostics company Cereius. 23 June 2023
Four companies in the Asia Pacific region have taken out licenses with The Medicines Patent Pool (MPP) to manufacture generic versions of Tasigna (nilotinib). 22 June 2023
The US drug industry is not happy with the Inflation Reduction Act (IRA) and is pursuing broad legal action in an attempt to limit its impact. 22 June 2023
The US Food and Drug Administration (FDA) yesterday approved US pharma giant Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). 21 June 2023
Adcendo, a Danish biotech focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has appointed Lone Ottesen its chief medical officer (CMO). 20 June 2023
The US Food and Drug Administration (FDA) has slapped a clinical hold on US biotech Arcellx’ CART-ddBCMA investigational new drug (IND) for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). 20 June 2023
China-headquartered biotech BeiGene says it is aware that Pharmacyclics has filed a complaint against BeiGene and its US subsidiary alleging that its lead product Brukinsa (zanubrutinib) infringes a patent issued on June 13, 2023, to Pharmacyclics, a subsidiary of US pharma major AbbVie. 19 June 2023
The US Food and Drug Administration (FDA) has extended the review period of the new drug application (NDA) for momelotinib by three months to provide time to review recently submitted data, according to a stock exchange filing by UK pharma major GSK. 16 June 2023
USA-based Mersana Therapeutics has announced that the US Food and Drug Administration (FDA) has issued a partial clinical hold pausing patient enrollment in UP-NEXT and UPGRADE-A, the trials of UpRi in platinum-sensitive ovarian cancer. 16 June 2023
The European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for fruquintinib. 16 June 2023
Indian drugmakers Alkem Laboratories and Lupin Limited have recently launched the world’s first cetuximab biosimilar in India for the treatment of head and neck cancer (HNC). 16 June 2023
Seagen has announced an update to the label for its antibody-drug conjugate Adcetris (brentuximab vedotin), adding results from the Phase III ECHELON-1 trial. 15 June 2023
UK-based ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, has acquired the scientific assets of Imagen Therapeutics from its appointed liquidators. 14 June 2023
French drugmaker Sanofi has placed a strong emphasis on the adoption of artificial intelligence capabilities to facilitate its internal operations. 13 June 2023
UK-headquartered biotech Tiziana Life Sciences has announced the appointment of Dr Matthew Davis as its new chief operating officer (COO). 13 June 2023
Seagen has announced latest efficacy and safety results from Part C of a Phase II trial of Adcetris (brentuximab vedotin) alongside nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as a frontline treatment for early-stage classical Hodgkin lymphoma (cHL). 13 June 2023
German radiopharmaceutical specialist ITM Isotope Technologies (ITM) has opened a new manufacturing facility for therapeutic radionuclides in its home town of Munich. 13 June 2023
Spanish drugmaker PharmaMar and China-based Luye Pharma have revealed that the New Drug Application (NDA) submission of lurbinectedin has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). 12 June 2023
The US regulator is to review a submission from British drugmaker AstraZeneca for capivasertib, in combination with Faslodex (fulvestrant), under the Priority Review scheme. 12 June 2023